Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Relationship between erectile function and sexual self-confidence: a path analytic model in men being treated with tadalafil


Sexual self-confidence has been shown to be associated with erectile function (EF) in men receiving PDE-5 inhibitor therapy; however, few studies have investigated the pathways (for example, sexual satisfaction, communication, time concerns and spontaneity) through which improvements in sexual self-confidence occur. This study examined this relationship using a path analysis model in men with ED enrolled in an open-label clinical trial of 20 mg tadalafil, administered on-demand over 12 weeks. International Index of Erectile Function and Psychological and Interpersonal Relationship Scales data were used to assess improvement in EF, sexual confidence and mediating variables. Controlling for baseline measures and covariates, the model indicated that change in sexual self-confidence was significantly associated with changes in EF (P<0.0001), sexual communication conflict (P=0.01), time concerns (P<0.0001) and spontaneity (P<0.0001). The total effect of EF on sexual self-confidence was 0.85, with 0.08 of this relationship indirectly mediated through time concerns and spontaneity. These data suggest that improved sexual confidence in men receiving treatment with a long-acting PDE-5 inhibitor occurs both directly via improved EF and indirectly via improved spontaneity and diminished time concerns.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1


  1. Althof SE . Quality of life and erectile dysfunction. Urology 2002; 59: 803–810.

    Article  Google Scholar 

  2. Althof SE, O'Leary MP, Cappelleri JC, Crowley AR, Tseng LJ, Collins S . Impact of erectile dysfunction on confidence, self-esteem and relationship satisfaction after 9 months of sildenafil citrate treatment. J Urol 2006; 176: 2132–2137.

    CAS  Article  Google Scholar 

  3. Araujo AB, Durante R, Feldman HA, Goldstein I, McKinlay JB . The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med 1998; 60: 458–465.

    CAS  Article  Google Scholar 

  4. NIH Consensus Conference. NIH consensus development panel on impotence. Impotence. JAMA 1993; 270: 83–90.

    Article  Google Scholar 

  5. Tsertsvadze A, Yazdi F, Fink HA, MacDonald R, Wilt TJ, Soares-Weiser K et al. Diagnosis and treatment of erectile dysfunction. Agency for Healthcare Research and Quality: Rockville, MD, 2009 Report No. 09: E016.

    Google Scholar 

  6. Seftel AD, Buvat J, Althof SE, McMurray JG, Zeigler HL, Burns PR et al. Improvements in confidence, sexual relationship and satisfaction measures: results of a randomized trial of tadalafil 5 mg taken once daily. Int J Impot Res 2009; 21: 240–248.

    CAS  Article  Google Scholar 

  7. Sharlip ID, Shumaker BP, Hakim LS, Goldfischer E, Natanegara F, Wong DG . Tadalafil is efficacious and well tolerated in the treatment of erectile dysfunction (ED) in men over 65 years of age: results from Multiple Observations in Men with ED in National Tadalafil Study in the United States. J Sex Med 2008; 5: 716–725.

    CAS  Article  Google Scholar 

  8. Althof SE, O' Leary MP, Cappelleri JC, Glina S, King R, Tseng LJ et al. Self-esteem, confidence, and relationships in men treated with sildenafil citrate for erectile dysfunction: results of two double-blind, placebo-controlled trials. J Gen Intern Med 2006; 21: 1069–1074.

    Article  Google Scholar 

  9. Seidman SN, Roose SP, Menza MA, Shabsigh R, Rosen RC . Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am J Psychiatry 2001; 158: 1623–1630.

    CAS  Article  Google Scholar 

  10. Giuliano F, Pena BM, Mishra A, Smith MD . Efficacy results and quality-of-life measures in men receiving sildenafil citrate for the treatment of erectile dysfunction. Qual Life Res 2001; 10: 359–369.

    CAS  Article  Google Scholar 

  11. Ralph D, Eardley I, Kell P, Dean J, Hackett G, Collins O et al. Improvement in erectile function on vardenafil treatment correlates with treatment satisfaction in both patients and their partners. BJU Int 2007; 100: 130–136.

    CAS  Article  Google Scholar 

  12. Rosen R, Goldstein I, Huang XY, Bangerter K, Taylor T . The treatment satisfaction scale (TSS) is a sensitive measure of treatment effectiveness for both patients and partners: results of a randomized controlled trial with vardenafil. J Sex Med 2007; 4: 1009–1021.

    CAS  Article  Google Scholar 

  13. Nobre PJ . Psychological determinants of erectile dysfunction: testing a cognitive-emotional model. J Sex Med 2010; 7: 1429–1437.

    Article  Google Scholar 

  14. Masters WH, Johnson VE . Human Sexual Inadequacy. Bantam Books: Toronto; New York, 1970.

    Google Scholar 

  15. Kaplan HS . The New Sex Therapy. Brunner/Mazel: New York, 1974.

    Google Scholar 

  16. Althof SE, Berner MM, Goldstein I, Claes HI, Cappelleri JC, Bushmakin AG et al. Interrelationship of sildenafil treatment effects on the physiological and psychosocial aspects of erectile dysfunction of mixed or organic etiology. J Sex Med 2010; 7: 3170–3178.

    CAS  Article  Google Scholar 

  17. Rosen RC, Seidman SN, Menza MA, Shabsigh R, Roose SP, Tseng LJ et al. Quality of life, mood, and sexual function: a path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms. Int J Impot Res 2004; 16: 334–340.

    CAS  Article  Google Scholar 

  18. Morgentaler A, Barada J, Niederberger C, Donatucci C, Garcia CS, Natanegara F et al. Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: Use of a novel noninferiority study design. J Sex Med 2006; 3: 492–503.

    CAS  Article  Google Scholar 

  19. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A . The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–830.

    CAS  Article  Google Scholar 

  20. Swindle RW, Cameron AE, Lockhart DC, Rosen RC . The psychological and interpersonal relationship scales: assessing psychological and relationship outcomes associated with erectile dysfunction and its treatment. Arch Sex Behav 2004; 33: 19–30.

    Article  Google Scholar 

  21. Swindle R, Cameron A, Rosen R . A 15-item short form of the psychological and interpersonal relationship scales. Int J Impot Res 2006; 18: 82–88.

    CAS  Article  Google Scholar 

  22. Rosen R, Broderick G, Shabsigh R, Swindle R, Lockhart D, Cameron A . Sensitivity of the psychological and interpersonal relationship scales to oral therapies for erectile dysfunction. J Sex Med 2005; 2: 461–468.

    Article  Google Scholar 

  23. Bollen KA . Structural Equations with Latent Variables. John Wiley & Sons: New York, 1989.

    Book  Google Scholar 

  24. Loehlin JC . Latent Variable Models: An Introduction to Factor, Path and Structural Analysis 4th edn. Lawrence Erlbaum Associates: Mahwah, NJ, 2004.

    Google Scholar 

  25. Rubio-Aurioles E, Porst H, Kim ED, Montorsi F, Hackett G, Morales AM et al. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med 2012; 9: 1418–1429.

    CAS  Article  Google Scholar 

  26. Eardley I, Mirone V, Montorsi F, Ralph D, Kell P, Warner MR et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 2005; 96: 1323–1332.

    CAS  Article  Google Scholar 

  27. Dean J, Hackett GI, Gentile V, Pirozzi-Farina F, Rosen RC, Zhao Y et al. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study. J Sex Med 2006; 3: 650–661.

    CAS  Article  Google Scholar 

Download references


We acknowledge New England Research Institutes employees May Yang, MPH and Heather Litman, PhD for statistical analysis and interpretation and Andre Araujo, PhD for scientific consultation on the statistical analysis plan and data interpretation. We also acknowledge Stephanie Brillhart of PharmaNet/i3 for writing and editorial support for the manuscript. This study was sponsored by Eli Lilly.

Author information

Authors and Affiliations


Corresponding author

Correspondence to A Sontag.

Ethics declarations

Competing interests

Dr Sontag is an employee of and stockholder in Eli Lilly. Dr Ni is an employee of and stockholder in Eli Lilly. Dr Althof has consulted for Abbott, Bayer, Eli Lilly, Palitan Pharmaceuticals and Promenescent. Dr Rosen has consulted for Auxilium, Bayer Healthcare, Eli Lilly and Palatin Pharmaceuticals.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sontag, A., Ni, X., Althof, S. et al. Relationship between erectile function and sexual self-confidence: a path analytic model in men being treated with tadalafil. Int J Impot Res 26, 7–12 (2014).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • ED
  • path analytic model
  • PDE-5 inhibitor
  • sexual self-confidence
  • tadalafil

Further reading


Quick links